Guillermo de Velasco

Author

Spanish National Cancer Research Centre

Also Known As

G. De Velasco, G. de Velasco, Guillermo De Velasco, Guillermo de Velasco

Publications

521

Citations

H-Index

Concepts

All Affiliations

Spanish National Cancer Research Centre Complejo Hospitalario de Navarra Hospital Universitario 12 De Octubre Research Institute Hospital 12 de Octubre HM Hospitales

About

Guillermo de Velasco is an author at Spanish National Cancer Research Centre specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	153
2	Pathology	3	3	93
3	Pharmacology	2	2	60
4	Surgical Oncology	2	2	60
5	Immunology	1	1	25

Guillermo de Velasco

Publications

205

Citations

H-Index

Page 1

	Year	Citations
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome Juan María Roldán‐Romero, María Santos, Javier Lanillos, Modern Pathology Molecular CharacterizationUrologyPathway AlterationsPoor OutcomeGenitourinary Cancer	2020	48
Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial. Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Inmaculada Fernández, Journal of Clinical Oncology Molecular CharacterizationUrologySurgical OncologyCisplatin-based ChemotherapyHrd Tumor	2020	43
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis Alberto Carretero-González, Marta Hergueta‐Redondo, Sara Sánchez‐Redondo, OncoImmunology Tumor InnervationImmunologyPathologyExtracellular MicrovesiclesHigh-grade Gliomas	2022	25
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors Aristotelis Bamias, Axel S. Merseburger, Yohann Loriot, Journal for ImmunoTherapy of Cancer	2023	21
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma María Santos, Javier Lanillos, Juan María Roldán‐Romero, Genetics in Medicine Pathogenic Germline VariantsUrologyGenitourinary CancerMedicinePathology	2021	20
SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018) Aranzazu González del Alba, Guillermo de Velasco, Núria Laínez, Clinical & Translational Oncology	2018	19
761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial Juan Francisco Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández, Annals of Oncology Surgical OncologyUrologyGenitourinary CancerMedicinePharmacology	2020	17
Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study J. Connor Wells, Shaan Dudani, Chun Loo Gan, Clinical Genitourinary Cancer	2021	12

Page 1